- Home
- UNH vs NVO Comparison
UNH vs NVO Comparison
Compare UNH & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNH
- NVO
- Stock Information
- Founded
- UNH 1977
- NVO 1923
- Country
- UNH United States
- NVO Denmark
- Employees
- UNH N/A
- NVO N/A
- Industry
- UNH Medical Specialities
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNH Health Care
- NVO Health Care
- Exchange
- UNH Nasdaq
- NVO Nasdaq
- Market Cap
- UNH 279.9B
- NVO 278.0B
- IPO Year
- UNH 1984
- NVO N/A
- Fundamental
- Price
- UNH $348.18
- NVO $54.29
- Analyst Decision
- UNH Buy
- NVO Buy
- Analyst Count
- UNH 25
- NVO 7
- Target Price
- UNH $387.63
- NVO $98.00
- AVG Volume (30 Days)
- UNH 19.5M
- NVO 14.9M
- Earning Date
- UNH 10-14-2025
- NVO 11-05-2025
- Dividend Yield
- UNH 2.54%
- NVO 2.27%
- EPS Growth
- UNH 52.72
- NVO 24.25
- EPS
- UNH 23.12
- NVO 3.93
- Revenue
- UNH $422,818,000,000.00
- NVO $49,108,936,497.00
- Revenue This Year
- UNH $13.05
- NVO $10.01
- Revenue Next Year
- UNH $3.96
- NVO $9.93
- P/E Ratio
- UNH $15.06
- NVO $13.81
- Revenue Growth
- UNH 9.70
- NVO 20.91
- 52 Week Low
- UNH $234.60
- NVO $45.05
- 52 Week High
- UNH $630.73
- NVO $138.22
- Technical
- Relative Strength Index (RSI)
- UNH 77.15
- NVO 43.87
- Support Level
- UNH $303.70
- NVO $54.60
- Resistance Level
- UNH $312.89
- NVO $57.35
- Average True Range (ATR)
- UNH 9.16
- NVO 1.15
- MACD
- UNH 3.82
- NVO 0.34
- Stochastic Oscillator
- UNH 93.86
- NVO 27.94
About UNH UnitedHealth Group
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.